In obesity, how does pharmacokinetics change for lipophilic versus hydrophilic drugs, and how should dosing be adjusted?

• A. Lipophilic drugs have decreased Vd in obesity, requiring lower loading doses.
• B. Lipophilic drugs are unaffected by obesity; hydrophilic drugs require higher loading doses.
• C. Lipophilic drugs show increased Vd with obesity and may require higher loading doses; hydrophilic drugs may be less affected.
• D. Obesity does not change dosing strategies.

Answer: (C)

Obesity changes how drugs distribute in the body because body composition shifts toward more adipose tissue and more extracellular fluid. Lipophilic drugs readily partition into fat, so their volume of distribution increases in obesity. Those drugs end up with a larger reservoir to occupy, which lowers peak plasma concentrations after a given dose and can prolong the time to reach therapeutic levels. Because of the expanded distribution space, achieving the desired concentration quickly often requires a higher loading dose, and this dose is frequently guided by total body weight for lipophilic agents.

Hydrophilic drugs, on the other hand, stay mainly in lean tissue and extracellular fluid, so their distribution volume is less affected by excess fat. Their loading doses are less likely to need a substantial increase, and clinicians may rely on ideal or adjusted body weight to avoid overdosing. Keep in mind that obesity can still influence clearance for some drugs, so maintenance dosing and monitoring are important, but the key distinction is the larger impact of obesity on the distribution of lipophilic drugs versus the relatively smaller effect on hydrophilic ones.